Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead, With Two PRVs In Hand, Holds Options For Accelerating Late-Stage Pipeline

Executive Summary

Likely candidates for use of Gilead's priority review vouchers include GS-4997, a Phase III candidate for NASH, and bictegravir, its second-generation integrase inhibitor for HIV. The virology specialist previously used a PRV successfully to accelerate approval of Odefsey.

You may also be interested in...



Deals Of The Year: Cast Your Vote For Top Financing Of 2017

It's time for In Vivo's 10th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners. (It's free.)

ViiV's Two-Drug HIV Tablet Juluca Is Disruptive, Yet Uptake May Be Slow

Pricing of $31,000 annually for GSK/J&J's single-tablet, two-drug HIV regimen Juluca (dolutegravir/rilpivirine) is on par with marketed fixed-dose combinations that include integrase inhibitors.

Keeping Track: HIV Filings Include Novel Agent From Gilead, Viiv's Two-Drug Maintenance Regimen

The latest HIV drug development news and highlights from our FDA Performance Tracker.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

WI964856

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel